For decades, healthcare largely followed a reactive model, intervening once disease manifests. But with over 5.8 million annual deaths from non-communicable diseases (NCDs), rising metabolic disorders, infertility challenges, lifestyle-linked chronic conditions, and an aging population, the country is witnessing a decisive shift toward preventive, science-backed healthcare.
At the center of this transformation stands Universal NutriScience (UNS), a company redefining nutraceuticals from “adjunct supplements” to clinically validated therapeutic solutions.
From Consumer Supplements to Clinical Science
India’s nutraceutical universe remains predominantly consumer driven. Nearly 70–80% of the market flows directly through retail channels, with only 20–30% routed through doctors under scientific supervision.
This structural imbalance often results in inconsistent dosing, variable outcomes, and limited clinical oversight.
UNS has deliberately positioned itself in the more demanding but far more credible segment, doctor-driven, evidence-based nutraceuticals.
Rather than competing in commoditized over-the-counter wellness, UNS has built a pure-play, therapy-focused platform anchored in:
- Randomized clinical evidence
- Defined dosage protocols
- Pharmaceutical-grade manufacturing
- Novel Drug Delivery Systems (NDDS)
- Measurable therapeutic outcomes
Modern healthcare practitioners demand proof. Patients demand safety. The nutraceutical industry is undergoing a “pharmaceuticalization,” blending the safety of natural compounds with the rigor of clinical science. UNS is at the forefront of this shift.This model is particularly powerful in chronic and lifestyle-linked conditions where:
- Long-term drug therapy has safety limitations
- Lifestyle intervention is critical
- Preventive support can delay invasive procedures
Universal NutriScience: Building India’s Most Trusted Nutraceutical Platform
Born from a strategic partnership between Kedaara Capital and Universal Medicare, UNS has rapidly emerged as a science-led, innovation-driven nutraceutical platform.
With a 30-year manufacturing heritage, access to world-class R&D infrastructure, and strong private equity backing, UNS combines:
- Scientific rigor
- Therapeutic specialization
- Field execution strength
- Digital-forward engagement
- Structured talent architecture
UNS is not chasing trends, it is shaping therapeutic categories.Dominance in Women’s Health & Fertility
Infertility is no longer a niche concern. Delayed parenthood, stress, metabolic disorders, and environmental factors have made reproductive health a rising public health priority.
UNS has carved a leadership position in fertility science through its dominant presence in Coenzyme Q10 (CoQ).
CoQ: From Early Intervention to Advanced Support
CoQ plays a central role in mitochondrial energy production, directly influencing:
- Oocyte quality
- Sperm motility
- Sperm count
- Oxidative stress balance
UNS’ CoQ portfolio is designed across the entire fertility journey, from early diagnosis to advanced assisted reproductive stages.Its therapy coverage spans:
- Couple therapy frameworks
- Support in Poor Ovarian Response
- Support for diminishing ovarian reserve
- Libido management
- Erectile dysfunction support
- Sperm parameter optimization
- Sperm count enhancement
This stage-wise therapeutic coverage reflects a continuum-of-care philosophy, not isolated product selling.
The result: clinically supervised nutraceutical intervention integrated into reproductive protocols rather than positioned as general supplementation.
Women’s Health: Addressing the Silent Burden
India’s demographic profile underscores the magnitude of unmet need.
Women aged 15–44 years represent nearly 22% of the population, approximately 330 million individuals. Within this group:
- Nearly 45% experience Premenstrual Syndrome (PMS)
- Only about 27% are formally diagnosed
- Less than 10% receive structured treatment
Millions silently endure cyclical pain, mastalgia, benign breast disorders, hormonal imbalance, and reduced quality of life.
UNS has addressed this gap through clinically supported hormonal wellness solutions, including GLA-rich Evening Primrose Oil formulations, positioned under medical guidance.
This is not symptom masking.
It is structured hormonal support rooted in scientific evidence.
Sakhi: Science with Social Responsibility
Beyond commercial ambition, UNS recognizes its social responsibility.
Through its Sakhi CSR initiative, the company drives awareness and education around menstrual health and hormonal wellness across, Schools, Colleges and Rural communities
Sakhi focuses on:
- Early symptom recognition
- Reducing stigma
- Improving diagnosis rates
- Promoting safe therapeutic pathways
By extending preventive science beyond prescriptions, UNS is strengthening community-level healthcare literacy while reinforcing its long-term therapeutic ecosystem.
Preventive Orthopedics: Delaying Invasive Interventions
India’s osteoarthritis burden is expanding rapidly.
UNS’ collagen portfolio supports cartilage health through optimized bioavailability and quality sourcing. Under medical supervision, structured collagen supplementation can help delay invasive procedures such as Total Knee Replacement (TKR) in select patient populations.
This represents preventive orthopedics, proactive joint preservation rather than post-surgical recovery.
General Wellness: From Legacy Brands to Lifestyle Interventions
Immunity awareness post-pandemic reshaped consumer behavior permanently.
UNS brands such as Seacod (Cod liver oil / fish oil) continue to see strong preference among children and adults for immunity and metabolic support.
But the shift is deeper, these products are no longer “seasonal immunity boosters.” They are daily lifestyle interventions integrated into preventive healthcare routines.
Leadership Perspectives
The CEO’s Vision: Pratin Vete on Scaling with Purpose
With leadership stints across global and Indian pharma majors including Novartis, Sanofi, Cipla, and Emcure, CEO Pratin Vete brings a transformational mindset to UNS.
He believes nutraceuticals are no longer optional adjuncts, they are preventive pillars.
“There is a clear and growing medical acceptance of nutraceuticals as preventive and supportive therapies. During COVID, immunity-supporting therapies witnessed exponential demand. Even today, consumers actively seek evidence-backed solutions.”
He emphasizes that nutraceuticals meaningfully complement pharmaceuticals in improving therapy outcomes, whether in fertility, osteoarthritis, PMS, or metabolic health.
“Our goal is to build a portfolio admired by both doctors and patients. We are strengthening digital engagement, scientific education, and field capability to ensure UNS becomes the first choice in preventive healthcare.”
The Strategic Outlook: Dr. Shailesh Ayyangar, Chairman, UNS on Precision Prevention & Innovation
Dr. Shailesh Ayyangar knows UNS brands for more than 15 years, having acquired this business in 2010 when he was running Sanofi business in India. He strongly believes that future of holistic health lies as much in evidence-based nutraceuticals as in science backed pharmaceuticals.
“India’s rising disease burden and ageing demographic demand research-driven preventive concepts. The next decade belongs to evidence-based nutraceuticals that are integrated into standard-of-care protocols.”
He believes the competitive advantage lies not merely in product availability, but in scientific depth and disciplined execution.
“We are not in the business of selling vitamins. We are in the business of delivering clinically relevant lifestyle interventions. The future is precision nutrition, right molecule, right patient, right stage of disease.”
Dr. Ayyangar credits UNS’s success to the R&D ecosystem of Universal Medicare, combined with the strategic capital and governance discipline of Kedaara Capital which creates a rare blend of:
- Innovation capability
- Manufacturing excellence
- Clinical credibility
- Scalable execution
“Our mission is to build a nutraceutical platform that doctors trust, patients rely on, and investors believe in, across every stage of life.”
The UNS Growth Trajectory: From Foundation to ₹1000 Cr Vision
UNS is not just building brands. It is building therapeutic franchises.
With structured field expansion, therapy-focused portfolio strategy, digital-first engagement, and strong talent architecture, the company is positioning itself to:
- Expand dominance in Women’s Health
- Deepen presence in Urology, Cardiovascular, Oncology & Diabetology adjacencies
- Strengthen Direct to Consumer (D2C) capabilities
- Leverage global sourcing & partnerships
- Scale toward a ₹1000 Cr ambition by FY28 – through organic and inorganic roadmap.
The organization’s people-first culture, leadership bench strength, and performance-driven sales architecture create the backbone for sustainable scale.
Defining the New Standard of Care
As India accelerates toward preventive healthcare adoption, UNS is not merely participating in market growth, it is defining category benchmarks.
Through scientific rigor, portfolio innovation, disciplined execution, and visionary leadership, Universal NutriScience is transforming nutraceuticals into an integral component of India’s healthcare continuum.
- From fertility to joint care.
- From hormonal balance to immunity.
- From supplementation to clinical precision.
UNS is powering India’s shift from reactive medicine to preventive science.
Source link
#Clinical #Pivot #Universal #NutriScience #Rewriting #Preventive #Healthcare #India
